- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 23256-42-0] Trimethoprim lactate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0510C |
| Brand: | MCE |
| CAS: | 23256-42-0 |
Overview
| MDL | MFCD00171722 |
|---|---|
| Molecular Weight | 380.40 |
| Molecular Formula | C17H24N4O6 |
| SMILES | CC(O)C(O)=O.NC1=NC=C(CC2=CC(OC)=C(OC)C(OC)=C2)C(N)=N1 |
3 Publications Citing Use of MCE
Summary
Trimethoprim lactate is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim lactate is active against a wide range of Gram-positive and Gram-negative aerobic bacteria . Trimethoprim lactate has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim lactate can inhibit infection of Influenza A virus in chick embryo when combinated with zinc [1] [2] [3] [4] .
In Vitro
Trimethoprim interrupts folate metabolism by inhibition of the activity of dihydrofolase reductase (DHFR), which reduces dihydrofolate to tetrahydrofolate (THF)
[1]
.
Trimethoprim (3 μg/mL; 1 h) induces protein aggregation and main heat shock proteins (Hsps) in E. coli cells, which indicates that Trimethoprim sulfate presence leads to protein misfolding
[1]
.
Trimethoprim (1.5-3 μg/mL; 1 h) causes induction of DnaK, DnaJ, GroEL, ClpB, and IbpA/B Hsps in
E. coli
cells exposed to folate and heat stress
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Trimethoprim (10 mg/kg; i.v.; once every 12 h; 3 d) shows antibacterial activity against
H. influenzae
,
S. pneumoniae
,
E. coli
and
N. meningitidis
in infected mice
[2]
.
Trimethoprim can be connected with the thiomaltose (TM-TMP) and shows stability with a half-life of about 1 hour in complete serum, and has an MIC value around 1 μM against
E. coli
[2]
.
Trimethoprim (10 mg/mL; 0.5 mL; inject with Trimethoprim-Zn combined suspension) decreases the virus titer and increases the survival rate of chicken embryo
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female C3H/HeOuJ mice (transurethrally infected with a 50 μL suspension containing 1-2×10 7 CFU of E. coli under 3% isoflurane) [2] |
| Dosage: | 10 mg/kg |
| Administration: | i.v.; once every 12 h; for 3 d |
| Result: | Showed antibacterial activity against H. influenzae , S. pneumoniae , E. coli and N. meningitidis with CD 50 s of 150 mg/kg, 335 mg/kg, 27.5 mg/kg and 8.4 mg/kg, respectively in infected mice. |
| Animal Model: | Fertilized eggs (injected H3N2 virus into amniotic and allantoic space at day 8) [4] |
| Dosage: | 10 mg/mL; 0.5 mL |
| Administration: | The Trimethoprim-Zn combined suspension was injected into the air sac; single dosage |
| Result: |
Decreased the virus titer and increased the survival rate of chicken embryo.
The survival rate peaked at ratio about 0.18 (Zn/Trimethoprim). |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00752375 | University of Alberta|Canadian Urological Association |
Pyelonephritis
|
February 2009 | Phase 3 |
| NCT02879981 | Hoffmann-La Roche |
Bronchitis
|
November 10, 2016 | |
| NCT01137903 | Universidad Complutense de Madrid |
Osteomyelitis|Diabetic Foot|Diabetic Foot Ulcers
|
April 2010 | Not Applicable |
| NCT00869518 | University of California, San Francisco |
Staphylococcus Aureus|HIV Infections
|
July 2009 | Phase 2 |
| NCT02902640 | Hoffmann-La Roche |
Bronchitis
|
November 15, 2016 | |
| NCT00078559 | University of Wisconsin, Madison|Immune Tolerance Network (ITN) |
Kidney Transplantation|Kidney Disease
|
November 2003 | Phase 1|Phase 2 |
| NCT00014911 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Diabetes Mellitus, Insulin-Dependent
|
April 2001 | Phase 2 |
| NCT00002002 | Lederle Laboratories|NIH AIDS Clinical Trials Information Service |
Pneumonia, Pneumocystis Carinii|HIV Infections
|
Not Applicable | |
| NCT02188472 | Henrik Enghusen Poulsen|Klinisk Biokemisk Afdeling|Klinisk farmakologisk Afdeling|Sektion for Biomedicin Institut for Veterinær Patobiologi|Rigshospitalet, Denmark |
Oxidative Stress
|
November 2010 | Phase 1 |
| NCT00002120 | U.S. Bioscience|Jacobus Pharmaceutical|NIH AIDS Clinical Trials Information Service |
Pneumonia, Pneumocystis Carinii|HIV Infections
|
Phase 1 | |
| NCT01140516 | McMaster University|The Physicians´ Services Incorporated Foundation|Hamilton Health Sciences Corporation|McMaster Surgical Associates |
Hydronephrosis|Urinary Tract Infection
|
July 2010 | Not Applicable |
| NCT03746106 | University of California, San Francisco|Tufts University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Davis |
Vitamin B1 Deficiency|Thiamine Deficiency
|
January 28, 2019 | Phase 4 |
| NCT03919435 | University of Pennsylvania |
Granulomatosis With Polyangiitis|Wegener Granulomatosis
|
March 27, 2019 | Phase 1|Phase 2 |
| NCT00002850 | Gary Morrow|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|University of Rochester |
Infection|Multiple Myeloma
|
March 1997 | Phase 3 |
| NCT00141037 | National Institute of Allergy and Infectious Diseases (NIAID)|Astellas Pharma Inc|Hoffmann-La Roche |
Kidney Diseases|Kidney Transplantation|Kidney Transplant|Renal Transplantation|Renal Transplant
|
March 2004 | Phase 1|Phase 2 |
| NCT00380640 | The Hospital for Sick Children |
Epidermolysis Bullosa
|
September 2006 | Phase 2 |
| NCT02145338 | Newcastle-upon-Tyne Hospitals NHS Trust|NHS Health Technology Assessment Programme|Newcastle University|Glasgow Caledonian University|University of Aberdeen|Cambridge University Hospitals NHS Foundation Trust|North Bristol NHS Trust|University of Southampton |
Urinary Tract Infections, Recurrent
|
September 2013 | Phase 4 |
| NCT01820897 | JOSE MANUEL ARREOLA GUERRA|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Urinary Tract Infection|Asymptomatic Bacteriuria|Allograft Rejection|Microbiologic Resistance|Hospitalization
|
April 2013 | Phase 4 |
| NCT03173053 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|University College, London |
Staphylococcus Aureus|Motility Disorder
|
February 8, 2018 | Not Applicable |
| NCT02371603 | GlaxoSmithKline |
Anaemia
|
February 11, 2015 | Phase 1 |
| NCT03077711 | NorthShore University HealthSystem |
Urinary Tract Infections, Recurrent
|
June 2016 | Phase 4 |
| NCT05418777 | William Beaumont Hospitals |
COPD Exacerbation Acute
|
September 28, 2022 | Phase 1|Phase 2 |
| NCT05398679 | Fundacion Clinic per a la Recerca Biomédica |
Endocarditis Infective
|
June 1, 2022 | Phase 4 |
| NCT03235947 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Laboratorios Senosiain, S.A. de C.V. |
Urinary Tract Infection|Asymptomatic Bacteriuria
|
September 7, 2016 | Phase 4 |
| NCT01757236 | University Hospital, Tours|Pfizer|International Clinical Trials Association |
Hip Prosthetic Joint Infection
|
October 2012 | Phase 2 |
| NCT00002283 | Jacobus Pharmaceutical|NIH AIDS Clinical Trials Information Service |
Pneumonia, Pneumocystis Carinii|HIV Infections
|
Not Applicable | |
| NCT05268120 | Leiden University Medical Center |
MRSA
|
July 25, 2022 | Not Applicable |
| NCT04306731 | University of Sulaimani |
Recurrent Urinary Tract Infection
|
September 20, 2014 | Not Applicable |
| NCT03489629 | University of North Carolina, Chapel Hill|University of Washington|Cook Children´s Medical Center|Indiana University|University of Michigan|University of Texas Southwestern Medical Center|St. Louis Children´s Hospital |
Cystic Fibrosis
|
April 3, 2018 | Phase 2 |
| NCT01507974 | HaEmek Medical Center, Israel |
Pregnancy Complications
|
January 16, 2012 | Not Applicable |
| NCT05274672 | Baylor Research Institute|Albert Einstein Healthcare Network |
Benign Prostatic Hyperplasia|Urinary Tract Infections
|
March 1, 2022 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 250 mg/mL ( 657.20 mM ; Need ultrasonic)
H 2 O : 16.67 mg/mL ( 43.82 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6288 mL | 13.1441 mL | 26.2881 mL |
| 5 mM | 0.5258 mL | 2.6288 mL | 5.2576 mL |
| 10 mM | 0.2629 mL | 1.3144 mL | 2.6288 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution
-
4.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (5.26 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] Ewa Laskowska, et al. Trimethoprim Induces Heat Shock Proteins and Protein Aggregation in E. Coli Cells. Curr Microbiol. 2003 Oct;47(4):286-9.
- [2] R N Brogden, et al. Trimethoprim: A Review of Its Antibacterial Activity, Pharmacokinetics and Therapeutic Use in Urinary Tract Infections. Drugs. 1982 Jun;23(6):405-30.
- [3] Xiaojian Wang, et al. A Trimethoprim Conjugate of Thiomaltose Has Enhanced Antibacterial Efficacy In Vivo. Bioconjug Chem. 2018 May 16;29(5):1729-1735.
- [4] El Habbal MH. Combination therapy of zinc and trimethoprim inhibits infection of influenza A virus in chick embryo. Virol J. 2021 Jun 3;18(1):113.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.